Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955913 · ClinicalTrials.gov registry record
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 3,679
- Enrollment target
NCT03955913: Completed study, sponsored by Janssen Research & Development.
NCT03955913 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 3,679 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03955913 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 3,679 participants
- Enrollment target
Study Summary
The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
Primary Outcome
Percentage of participants with selected FGFR gene aberrations will be assessed through molecular testing of their archival tumor tissue.
Interventions
- OTHER Archival Tumor Tissue Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,679 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2022-09-19 |
What the finished NCT03955913 record still lists
NCT03955913 is an observational study that tracks outcomes without assigning an intervention. Its 3,679 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Archival Tumor Tissue Sample is the first listed.
NCT03955913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03955913 about?
NCT03955913 is a clinical study titled "A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations". The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
What is the current status of trial NCT03955913?
This trial is currently completed. The enrollment target is 3,679 participants. The study started on 2019-08-01. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT03955913?
The interventions under investigation include: Archival Tumor Tissue Sample (OTHER).
Who is sponsoring clinical trial NCT03955913?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI